Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | PALB2 |
| Variant | del |
| Impact List | deletion |
| Protein Effect | loss of function |
| Gene Variant Descriptions | PALB2 del indicates a deletion of the PALB2 gene. |
| Associated Drug Resistance | |
| Category Variants Paths |
PALB2 mutant PALB2 inact mut PALB2 del |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| PALB2 del | ovarian cancer | sensitive | Saruparib | Preclinical - Cell culture | Actionable | In a preclinical study, Saruparib (AZD5305) inhibited colony formation in an ovarian cancer cell line with PALB2 deletion in culture (PMID: 35929986). | 35929986 |
| PALB2 del | uterus leiomyosarcoma | predicted - sensitive | Olaparib + Temozolomide | Case Reports/Case Series | Actionable | In a clinical case study, Lynparza (olaparib) and Temodar (temozolomide) combination treatment resulted in stable disease and progression-free survival lasting 381 days in a patient with advanced uterine leiomyosarcoma harboring a homozygous deletion of PALB2 (PMID: 37467452). | 37467452 |